News

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal wound healing.

Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.

Long-term data from the GLK-202-03 extension study show a sustained 1.9 D improvement in Kmax after a single epithelium-on cross-linking treatment, with no serious or treatment-related adverse events reported.

Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.

Arun C. Gulani, MD, introduces a keratoconus classification based on what prevents vision: visual, structural, or salvage.

A solo surgeon explains how automation replaced his front desk, scheduling, and billing staff.

Pivotal wet AMD, DME, and XLRP readouts; the MOGENRY BLA; and Retina Society, EURETINA, and ESCRS highlights from September.

At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.

September was one of the busiest months of the year in eye care—From ESCRS to Eyecon

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.

Host Deborah Ristvedt, DO, welcomes Dr. Mathews to discuss the relationships, passions, and intentional choices that have shaped her career as a cornea, cataract, and refractive surgeon, dry eye expert, and educator.

As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.

Sunir Garg, MD, FACS, previews DME and dry AMD data, free papers, and surgical sessions at AAO 2026.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.

Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface sessions headline AAO 2026.

Ritesh Narula, MBBS, MS, discusses phase 1 and early phase 2 results of the Eyestem subretinal stem cell study in geographic atrophy, including an 11-letter mean visual acuity gain maintained at 18 months.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.

João Pedro Marques, MD, MSc, PhD, FEBOphth, discusses the IRD-PT, a web-based Portuguese registry of roughly 2,400 patients with inherited retinal diseases that supports research and identifies patients for clinical trials.

Could one surgery replace years of GA injections? Phase 2 ArMaDa data suggest gene therapy OCU410 slows lesion growth.

At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and eplerenone for central serous chorioretinopathy.

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model being built with 108 partners from more than 40 countries

• The American Academy of Ophthalmology 2026 annual meeting is set for October 9-12 in New Orleans.

Kareem Moussa, MD, discusses how four local corticosteroid injections compare on effectiveness and IOP, and what that means for choosing among them.